9th Sep 2021 08:50
(Alliance News) - AstraZeneca PLC revealed Thursday that its study into the use of a combination of drugs to treat asthma has met all primary endpoints.
The drugmaker said a combination of albuterol and budesonide demonstrated "significant benefits for asthma patients" in the phase III trials, with a reduced risk of severe asthma exacerbations.
The drug combination, known as PT027, was also found to significantly improve lung function compared to individual use of the treatments in mild to moderate asthma sufferers.
"All patients with asthma are at risk of severe exacerbations, regardless of their disease severity and many are known to overuse short-acting bronchodilators. These exciting results with PT027 bring us one step closer to providing an innovative and superior treatment approach for asthma by preventing exacerbations," commented Mene Pangalos, executive vice president at Astra's BioPharmaceuticals Research & Development unit.
PT027 is a fixed-dose combination of albuterol and budesonide being developed by AstraZeneca and late-stage drug developer Avillion.
Shares were trading down 0.9% at 8,242.00 pence each early on Thursday morning in London.
By Will Paige; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca